Raymond James Maintains Outperform on Viking Therapeutics, Raises Price Target to $115
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Steven Seedhouse maintains an Outperform rating on Viking Therapeutics (NASDAQ:VKTX) and raises the price target from $37 to $115.
February 27, 2024 | 5:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James analyst Steven Seedhouse maintains an Outperform rating on Viking Therapeutics and raises the price target from $37 to $115.
The significant increase in the price target by a reputable analyst firm like Raymond James is likely to instill positive sentiment among investors, potentially driving up the stock price in the short term. The Outperform rating reaffirms the analyst's confidence in the company's prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100